Whitehouse Scientific’s managing director, Jamie Storey, showed his support for ‘Movember’ by joining more than 850,000 fellow ‘Mo Bros’ from around the world in growing facial hair throughout the month of November.
From humble beginnings, ‘Movember’ has become a global campaign aimed at raising vital funds and awareness for men’s health, specifically prostate and testicular cancer. It is one of a number of charity initiatives supported by the Whitehouse Scientific team.
‘Although I have spent the month looking a bit of a fool it was worth it for such a great cause,’ said Storey.
‘With awareness being the key, it was a pleasure explaining why I had grown a handlebar moustache to the many who have asked. I look forward to trying out a new style next year.’
Funds raised by ‘Movember’ in the UK are directed to The Prostate Cancer Charity and Institute of Cancer Research, which supports programmes aimed at increasing early cancer detection, diagnosis and effective treatments, and ultimately reducing the number of preventable deaths.
To date, ‘Movember’ has raised nearly £65m, with £15m coming from the UK. A total of £170m has been collected since 2004.
Whitehouse md grows moustache for charity
Joins fellow ‘Mo Bros’ around the world to raise funds and awareness for men’s health
You may also like
Manufacturing
Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Manufacturing
BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany
The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology
Finance
Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings
The firm has reported first-quarter earnings of $7.61bn and revenue of $15.17bn, both ahead of Wall Street forecasts, driven by robust GLP-1 sales and stronger-than-expected performance from its oral Wegovy pill
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Britain's biotech potential (part II): world-class science, second-class support?
In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale